The Children’s Tumor Foundation NF2-SWN Accelerator Initiative is dedicated to finding effective treatments for NF2-related schwannomatosis, or NF2-SWN (previously called neurofibromatosis type 2, or NF2). This powerful initiative is bringing treatments to the clinic (and patients) by expanding the clinical drug pipeline for NF2-SWN, improving drug selection through innovative testing models, and developing gene therapy options that address the underlying genetic causes of NF2-SWN.
As a global leader in NF research, the Children’s Tumor Foundation is dedicated to developing cures for all forms of NF. The Foundation and its partners bolstered the NF2-SWN research field through team science with Synodos for NF2, bringing together multidisciplinary scientists from 12 world-class labs. The Synodos teams shared information, datasets, and results in real-time at every step of research development and have since made that data freely available at nfdataportal.org.
That collaborative effort resulted in the identification of promising new clinical candidates for NF2-SWN. The NF2 Accelerator Initiative leverages this new knowledge into a new and ambitious structure with the goal of speeding up the drug discovery process. The NF2-SWN Accelerator Initiative’s three-pronged Phase One goals were fully funded and proved to have a far-reaching impact.
In 2022, the Initiative will continue the momentum and add a second phase to these endeavors, which will invest another $1.5 million toward drug discovery, clinical trials, and gene therapy for NF2-SWN. This important work will further the life-saving progress for patients living with NF2-SWN.
